Health Condition 1: K74- Fibrosis and cirrhosis of liver
Conditions
Interventions
Intervention1: Standard medical therapy plus Rifaximin for 6 months: All patients will receive medical therapy according to the standard guidelines for the management of the etiology and complications
Sponsors
AIIMS New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with cirrhosis (Child A and B) and sarcopenia 2. Age: 18-60 years
Exclusion criteria
Exclusion criteria: 1. Patients with history of overt hepatic encephalopathy (HE) or those who develop HE during treatment 2. Patients with sepsis, active GI bleed or acute kidney injury 3. Known cases of hepatocellular carcinoma 4. Any severe chronic illness including congestive heart failure, chronic kidney disease, neuromuscular disorders or HIV 5. History of any chronic drug intake such as corticosteroids 6. History of drugs postulated to increase muscle mass such as testosterone, growth hormone, anabolic steroids
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To compare the change in muscle mass at 6 months in patients receiving standard medical therapy (SMT) plus rifaximin compared to SMT alone.Timepoint: 0 and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To compare the change in muscle strength between the two groups at 6 months 2. To compare the change in muscle performance between the two groups at 6 months 3. To compare the change in quality of life between the two groups at 6 months 4. To compare the change in the plasma levels of ammonia between the two groups at 6 months Timepoint: 0 and 6 months | — |
Countries
India
Contacts
Public ContactDeepak Gunjan
All India Institute of Medical Sciences
Outcome results
None listed